DOCSLIB.ORG

Evotec Kauft US-Firma Für 256 Mio. Euro

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Evotec Kauft US-Firma Für 256 Mio. Euro Interview Cellact-Chefin Nalân Utku über den erfolgreichen Verkauf ihrer virtuellen Firma an Mundi- Wirtschaft. Technologie. Leben. 23. Jahrgang. 9|2017. pharma ISSN 1435-5272 | A 49017 25 JAHRE Morphosys feiert doppelt LESEPROBE DIGITALE MEDIZIN Deutschland will aufholen Expansion SPEZIAL Biosimilars drängen in Markt Evotec kauft US-Firma WAHL 2017 für 256 Mio. Euro Biopolitik in den Wahlprogrammen Bei Amgen sind biologische Arzneimittel in Qualität verwurzelt und werden von Zuverlässigkeit genährt. Eine solide Qualitätskontrolle und zuverlässige Versorgung sind genau so wichtig wie wissenschaftliche Innovationen. Seit mehr als drei Jahrzehnten wird bei Amgen jedes Medikament mit Engagement, Leidenschaft und dem Streben nach Perfektion hergestellt. Darum finden Sie bei Amgen die Biologika, die für die Behandlung Ihrer Patienten so enorm wichtig sind. Und das auch für die zukünftigen Generationen. Weitere Informationen über Amgens Engagement für eine gleichbleibende 8\HSP[p[\UKa\]LYSpZZPNL=LYZVYN\UNÄUKLU:PL\U[LY biotechnologybyamgen.de ©2013 Amgen Inc. Alle Rechte vorbehalten. AMG-DEU-AMG-021-2014-January-P (1/2014) 02_tk12_15_Amgen.indd 2 02.12.2015 15:22:22 Uhr European Biotechnology NETWORK Bundestagswahl I Stellt Euch vor, es ist Wahlkampf, und keiner kriegt‘s mit. Bis zum Redaktionsschluss jedenfalls konnte von Kampf um Wählerstimmen in Deutschland keine Rede sein. Die Regierende gibt wie üblich das Präsidenten-Surrogat, während es dem herausfordernden Dampfplauderer noch nicht einmal gelingt, aus dem Schatten seiner ver- staubten Partei zu treten. Die Grünen haben ein ernstes Verkalkungsproblem, die Populisten vom rechten und linken Rand verkünden ihr übliches dummes Zeug. Bei der FDP lässt sich noch nicht sagen, ob sie sich im Par- lament trauen wird, die von vielen vermisste Stimme der Andreas Mietzsch wirtschaftlichen Sachkenntnis und Vernunft zu erheben. Herausgeber Bräsigkeit und Behäbigkeit allerorten – totale Fehlan- zeige bei ökonomischen Zukunftsthemen. War da nicht was mit Globalisierung und Biologisierung der Industrie? Immerhin haben sechs der voraussichtlich sieben kommenden Bundestagsparteien biopolitische Positionen, die wir wie immer vor der Wahl in einer großen Übersicht zu- sammengetragen haben. Auf Seite 43 ff. geht es diesbezüglich zur Sache. Bundestagswahl II Falls Sie, liebe Leser, noch ein Beispiel für meinen Furor brauchen, denken Sie bitte an den so langsam verblassenden Abgasskandal. Die Elektroauto-Quote war da schon einer der größeren Aufreger. Aber niemand hat die allgemeine Entrüstung genutzt, um einmal weiterzudenken: Wäre es nicht ein guter Zeitpunkt, den herrschenden Mobili- tätsirrsinn grundsätzlich auf den Prüfstand zu stellen? Dass 68% der mehr als 40 Mio. Join the European deutschen Arbeitnehmer sich jeden Tag in ein tonnenschweres Blechgefährt setzen, Biotechnology Network! um zur Arbeit zu fahren, kann gar nicht ökologisch verträglich oder nachhaltig sein. Bewegungsmangel, Stickoxide, Lärm, Verkehrstote – der Steuerzahler bezahlt diesen The European Biotechnology Network Wahnsinn auch noch mit Pendlerpauschale und Dienstwagenregelung. Die Trennung is dedicated to facilitating co-operation von Arbeiten und Wohnen stammt aus den Zeiten industrieller Dinosaurier. Heute ist die between professionals in biotechnolo- Ausweisung von reinen Wohngebieten ein Anachronismus, der in den Führungsetagen gy and the life sciences all over Euro- der Autoindustrie zu mephistophelischem Kichern führen dürfte. Wir waren früher so- pe. This non-profit organisation brings gar schon mal weiter: Das Handwerk arbeitete im Hinterhaus, gewohnt wurde vorne. together research groups, universities, Größere Unternehmen bauten schönste Werkswohnungen für ihre Mitarbeiter – die SMEs, large companies and indeed all Siemensstadt in Berlin ist da ein beeindruckendes Beispiel. Und hier sind wir wieder actors in biotechnology. bei der Biotechnologie: Warum erdenken nicht biologisch geprägte Köpfe ganz neue städtebauliche Konzepte, die die Bedürfnisse von Menschen, Wirtschaft und Umwelt nachhaltig unter einen Hut bringen? Visionen, mit denen wir auch in einer globalisierten Do you want to know more about the Ökonomie ganz neue Märkte erschließen könnten? Die Autoindustrie war mal disruptiv advantages of a (free) membership? – vor mehr als 100 Jahren. Es ist höchste Zeit für etwas Neues! Vor diesem Hintergrund Just have a look at our website: ist der aktuelle Wahlkampf leider Zeitverschwendung. www.european-biotechnology.net Investoren „Exits“ sind ein zweischneidiges Schwert. Die NRW Bank kann sich über gleich zwei derartige Ereignisse in diesem Heft freuen: An Cellact (S. 20) und Evoxx (S. 22) war die erfolgreiche Förderbank maßgeblich beteiligt. Letzteres Unternehmen wurde nach Indi- European Biotechnology Network en verkauft. Mitsamt dem geistigen Eigentum allerdings, das zum Teil der Steuerzahler Rue de la Science 14b bezahlt hat. Die Firma war unter anderem Koordinator der vom BMBF geförderten In- 1040 Brusseles, Belgium novationsallianz FuPol: Funktionalisierte Polymere für die Bau- und Textilindustrie. Tel: +32 2 588 70 71 [email protected] |transkript. 09.2017. www.european-biotechnology.net INHALT. 8 Evotec übernimmt US-Konkurrenten 9/17 Für 300 Mio. US-Dollar kauft Evotec den Konkurrenten Aptuit. Das Ziel, ein Rundumsorglos- paket für Wirkstoffentwickler anbieten zu können, scheint damit in Reichweite. Anleger sind von Evotecs Wachstumsgeschichte überzeugt und der Börsenkurs geht durch die Decke. 14 Morphosys erhält erste Marktzulassung in den USA 25 Jahre nach ihrer Gründung feiert die Morphosys AG ihren bislang größten Erfolg: Der Antikörper Tremfya zur Behandlung der Schuppenflechte erhält die US-Marktzulassung. Es winken Meilensteinzahlungen von Lizenzpartner Janssen. 20 Mit unbeachteter Idee kommt Cellact zum 212 Mio. Euro-Exit Mundipharma sichert sich für 212 Mio. Euro den Zugriff auf Cellacts einzigen Vermögens- wert, den Wirkstoffkandidaten CAP7.1 gegen Gallengangkrebs. |transkript sprach mit der Gründerin Nalân Utku über CAP7.1 und die Wirkstoffforschung in Deutschland. 22 Evoxx: Für 7,65 Mio. Euro nach Indien verkauft Den Investoren von Evoxx gelingt nach zehn Jahren der Exit: Für 7,65 Mio. Euro übernimmt der indische Enzymhersteller Advanced Enzymes Technologies 100 % des Unternehmens. 43 Bundestagswahl 2017: Positionen der Parteien zur Biotechnologie Beginnen nach der Bundestagswahl blühende Zeiten für die Branche in Deutschland? |transkript hat die im Bundestag vertretenen Parteien, die FDP und die AfD nach ihren biopolitischen Zielen befragt und diese in einer großen Übersicht zusammengestellt. 47 Digitale Medizin: Die Politik schafft Fakten Das Rennen um die Analyse medizinischer Daten hat jetzt auch Deutschland erfasst. Fast zeitgleich präsentierten die Bundesregierung und der Freistaat Bayern Bio-IT-Pilotpro- jekte, die den kritischen deutschen Verbraucher von den Segnungen der Datenanalyse überzeugen sollen. 53 Entscheidender Fortschritt in der Alzheimer-Forschung Bis zum vorigen Jahr gab es kaum Anhaltspunkte dafür, was die Degeneration bei Alzheimer und Co. antreibt. Jetzt haben Schweizer Wissenschaftler entdeckt, dass die Mikroglia, das angeborene Immunsystem des Hirns, eine entscheidende Rolle spielt. 55 Roche baut Standort Penzberg kräftig aus In nur drei Jahren hat Roche rund 600 Mio. Euro in den Ausbau seines Standortes Penzberg gesteckt. Am Rande der Einweihung von fünf Neubauten gab der Konzern Einblicke in die Zukunft der personalisierten Medizin. 56 Pro & Kontra: Kostenexplosion durch personalisierte Medizin? Dem Arzneireport der Barmer zufolge steigen die Kosten für Onkologika, ohne dass das Gesamtüberleben verlängert wird. Dient die personalisierte Medizin nur als Vorwand für Preistreiberei? Abb.: Biocom AG, NxStage Medical Inc., Universität Zürich, jiris/fotolia.com, stockWERK/fotolia.com . 4 LESEPROBE |transkript. 9.2017. 6 AC Immune startet klinische 23 Erfolg für Biontechs Krebsimp- Antikörper-Programme / Roivant fung / Biognosys erweitert Serie Sciences erhält 1,1 Mrd. US- C-Finanzierung Dollar / Uni Düsseldorf leitet Reis- 24 Börse aktuell forscherkonsortium / Bioraffine- 25 Börsenkommentar rie-Förderinitiative gestartet 26 Fresenius Medical Care tätigt 7 Ethris überzeugt mit RNA- Milliarden-Zukauf / Plasma- Plattform / Immatics testet erste forschungsinitiative in Nieder- Krebsimmuntherapie / Merck sachsen gestartet strukturiert um / EBS Technolo- 46 Drastische Kostenunterschiede gies mit US-Expansionsplänen bei Medikamentenzulassung / © erwinova/fotolia.com 13 4 SC AG erreicht Jahreshoch / Eiertanz um e-Gesundheitskarte Teva baut in Ulm / Merck will 50 DFG investiert in deutsche Standorte schließen Sequenzierungsinfrastruktur Communication 16 |transkript persönlich / Aicuris‘ 51 RNA-Halbwertszeit kürzer als Pritelivir erhält Fast-Track-Status gedacht / Forum Sciences and + dissemination der FDA / Valneva findet Partner Health startet erfolgreich für Zika-Impfstoff 54 Drug Screening für Ungeborene services for 17 Stada von Bain und Cinven über- möglich nommen / Topas Therapeutics 56 TU München bekommt Campus- EU-funded consortia gewinnt ersten Pharmapartner / Zuwachs / Mikroalgenverbund Kuros spielt 17 Mio. CHF ein in Sachsen-Anhalt gegründet / Excellent R&D projects deserve 18 HR-Kommentar / Idorsia legt Kings College-Erweiterung in excellent communication. With more Phase II-Daten vor / Formycon Dresden nicht bestätigt than 30 years of experience in life verpartnert Stelara-Biosimilar / 59 Verbände sciences, BIOCOM is the perfect Marinomed bereit für
Load more

Recommended publications
  • MDAX—2019 Supervisory Board Study Key Insights from This Year’S Analysis by Russell Reynolds Associates
    MDAX—2019 Supervisory Board Study Key insights from this year’s analysis by Russell Reynolds Associates Summary Over the past year, Germany's MDAX companies have experienced significant change. The number of companies in the index increased by 10, bringing the overall total to 60. Moreover, 11 "old economy" firms, including Jungheinrich, Krones, Leoni, Salzgitter and Schaeffler, were ousted by pharma, med and biotech risers, such as Evotec, Morphosys, Qiagen, Sartorius and Siemens Healthineers, as well as "new economy" powerhouses like Dialog, Nemetschek, Software AG, Telefonica D, and United Internet. This was also an exceptional election year, with 106 shareholder representative positions expiring. All positions were filled. A total of 67 board members were re-elected, while 36 were replaced. The three remaining roles were absorbed by changes to board sizes. Female shareholder representation surpasses 30 percent For the first time, the share of female shareholder representatives surpassed the required quota, reaching 30.6 percent. Including employee representatives, women now make up 32 percent of supervisory board members. A total of three boards are now chaired by women. However, there is still a major gender discrepancy concerning positions of power when comparing chairpersonships and especially executive board positions. Only four companies can boast more than 30 percent of female executives, while 40 MDAX companies do not have a single woman in a leadership role. Accelerated increase in digital directors The number of digital directors on MDAX supervisory boards showed a significant 30 percent year- on-year increase. However, digital expertise is still unevenly spread in the MDAX. Seven companies have three or more digital directors, while 57 percent of boards completely lack digital expertise.
    [Show full text]
  • Fund Holdings
    Wilmington International Fund as of 7/31/2021 (Portfolio composition is subject to change) ISSUER NAME % OF ASSETS ISHARES MSCI CANADA ETF 3.48% TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD 2.61% DREYFUS GOVT CASH MGMT-I 1.83% SAMSUNG ELECTRONICS CO LTD 1.79% SPDR S&P GLOBAL NATURAL RESOURCES ETF 1.67% MSCI INDIA FUTURE SEP21 1.58% TENCENT HOLDINGS LTD 1.39% ASML HOLDING NV 1.29% DSV PANALPINA A/S 0.99% HDFC BANK LTD 0.86% AIA GROUP LTD 0.86% ALIBABA GROUP HOLDING LTD 0.82% TECHTRONIC INDUSTRIES CO LTD 0.79% JAMES HARDIE INDUSTRIES PLC 0.78% DREYFUS GOVT CASH MGMT-I 0.75% INFINEON TECHNOLOGIES AG 0.74% SIKA AG 0.72% NOVO NORDISK A/S 0.71% BHP GROUP LTD 0.69% PARTNERS GROUP HOLDING AG 0.65% NAVER CORP 0.61% HUTCHMED CHINA LTD 0.59% LVMH MOET HENNESSY LOUIS VUITTON SE 0.59% TOYOTA MOTOR CORP 0.59% HEXAGON AB 0.57% SAP SE 0.57% SK MATERIALS CO LTD 0.55% MEDIATEK INC 0.55% ADIDAS AG 0.54% ZALANDO SE 0.54% RIO TINTO LTD 0.52% MERIDA INDUSTRY CO LTD 0.52% HITACHI LTD 0.51% CSL LTD 0.51% SONY GROUP CORP 0.50% ATLAS COPCO AB 0.49% DASSAULT SYSTEMES SE 0.49% OVERSEA-CHINESE BANKING CORP LTD 0.49% KINGSPAN GROUP PLC 0.48% L'OREAL SA 0.48% ASSA ABLOY AB 0.46% JD.COM INC 0.46% RESMED INC 0.44% COLOPLAST A/S 0.44% CRODA INTERNATIONAL PLC 0.41% AUSTRALIA & NEW ZEALAND BANKING GROUP LTD 0.41% STRAUMANN HOLDING AG 0.41% AMBU A/S 0.40% LG CHEM LTD 0.40% LVMH MOET HENNESSY LOUIS VUITTON SE 0.39% SOFTBANK GROUP CORP 0.39% NOVARTIS AG 0.38% HONDA MOTOR CO LTD 0.37% TOMRA SYSTEMS ASA 0.37% IMCD NV 0.37% HONG KONG EXCHANGES & CLEARING LTD 0.36% AGC INC 0.36% ADYEN
    [Show full text]
  • Translation of Financial Statements As of 31 December 2020 And
    Translation of Financial Statements as of 31 December 2020 and Management Report Evotec SE Exhibit 1 Evotec SE, Hamburg Statement of financial position as of 31 December 2020 Assets 31.12.2020 31.12.2019 Equity and liabilities 31.12.2020 31.12.2019 EUR EUR EUR EUR A. Equity A. Fixed assets I. Subscribed capital 163.914.741,00 150.902.578,00 I. Intangible assets ./. nominal value Treasury shares -249.915,00 -249.915,00 Purchased franchises, industrial and similar rights 163.664.826,00 150.652.663,00 and assets, and licenses in such rights and assets 1.194.857,45 4.082.552,01 II. Capital reserves 482.139.820,51 243.587.164,27 II. Property, plant and equipment III. Reserve for treasury shares 249.915,00 249.915,00 1. Land, land rights and buildings, including buildings on third-party land 1.572.345,71 1.804.727,38 IV. Accumulated loss -100.132.424,27 -75.948.394,50 2. Plant and machinery 12.251.848,90 11.732.420,10 3. Other equipment, furniture and fixtures 1.160.417,33 1.035.981,29 545.922.137,24 318.541.347,77 4. Prepayments and assets under construction 1.315.392,83 1.118.311,65 16.300.004,77 15.691.440,42 III. Financial assets B. Provisions 1. Shares in affiliates 334.222.810,07 334.187.810,07 1. Provisions for pensions and similar obligations 169.091,00 166.780,00 2. Loans to affiliates 132.335.498,54 2.
    [Show full text]
  • FACTSHEET - AS of 28-Sep-2021 Solactive Mittelstand & Midcap Deutschland Index (TRN)
    FACTSHEET - AS OF 28-Sep-2021 Solactive Mittelstand & MidCap Deutschland Index (TRN) DESCRIPTION The Index reflects the net total return performance of 70 medium/smaller capitalisation companies incorporated in Germany. Weights are based on free float market capitalisation and are increased if significant holdings in a company can be attributed to currentmgmtor company founders. HISTORICAL PERFORMANCE 350 300 250 200 150 100 50 Jan-2010 Jan-2012 Jan-2014 Jan-2016 Jan-2018 Jan-2020 Jan-2022 Solactive Mittelstand & MidCap Deutschland Index (TRN) CHARACTERISTICS ISIN / WKN DE000SLA1MN9 / SLA1MN Base Value / Base Date 100 Points / 19.09.2008 Bloomberg / Reuters MTTLSTRN Index / .MTTLSTRN Last Price 342.52 Index Calculator Solactive AG Dividends Included (Performance Index) Index Type Equity Calculation 08:00am to 06:00pm (CET), every 15 seconds Index Currency EUR History Available daily back to 19.09.2008 Index Members 70 FACTSHEET - AS OF 28-Sep-2021 Solactive Mittelstand & MidCap Deutschland Index (TRN) STATISTICS 30D 90D 180D 360D YTD Since Inception Performance -3.69% 3.12% 7.26% 27.72% 12.73% 242.52% Performance (p.a.) - - - - - 9.91% Volatility (p.a.) 13.05% 12.12% 12.48% 13.60% 12.90% 21.43% High 357.49 357.49 357.49 357.49 357.49 357.49 Low 342.52 329.86 315.93 251.01 305.77 52.12 Sharpe Ratio -2.77 1.14 1.27 2.11 1.40 0.49 Max. Drawdown -4.19% -4.19% -4.19% -9.62% -5.56% -47.88% VaR 95 \ 99 -21.5% \ -35.8% -34.5% \ -64.0% CVaR 95 \ 99 -31.5% \ -46.8% -53.5% \ -89.0% COMPOSITION BY CURRENCIES COMPOSITION BY COUNTRIES EUR 100.0% DE
    [Show full text]
  • Evotec OAI AG Annual Report 2004 'Taking the Lead'
    Evotec OAI AG Annual Report 2004 ‘taking the lead’ Segment overview Evotec OAI operates through three Discovery Programs business divisions: Division (DPD) > Discovery Programs Division: Evotec OAI’s Discovery Programs Division proprietary drug candidates (DPD) is developing a deep portfolio of > Discovery and Development proprietary drug candidates. With years Services: contract research and of experience in assay development, development screening, chemistry and optimisation, > Tools and Technologies|Evotec Evotec OAI has established a strong Technologies: technologies and track record of successfully identifying instruments such candidates for its customers. In its proprietary research DPD has built up extensive knowledge about diseas- es of the central nervous system (CNS) through Evotec Neurosciences (ENS) and about metabolic disorders through the joint venture with DeveloGen. Through the acquisition of full ownership interest in ENS in March 2005, the Com- pany has now established its own attrac- tive CNS pipeline. DPD plans to rapidly progress the current programmes, to ex- pand these activities and to engage in early partnerships and|or out-license the drugs at proof-of-concept to the pharma- ceutical industry which is continuously searching for novel drug candidates to fill their clinical development pipelines. Discovery and Development Tools and Technologies Services (DDS) (Evotec Technologies|ET) Evotec OAI’s Discovery and Development Evotec Technologies (ET) is developing Services (DDS) division provides drug innovative drug discovery technolo- discovery contract research and develop- gies and instruments for the pharmaceu- ment support to a large group of global tical and biotechnology industries customers and to Evotec OAI’s internal and academic research institutions. The research in the Discovery Programs Company provides cutting-edge solu- Division.
    [Show full text]
  • Authorizations for Capital Raisings and Convertible Bond Issues
    Authorizations for Capital Raisings, Convertible Bond Issues and Share Repurchases (2019) German DAX® and MDAX® Companies clearygottlieb.com Preface This booklet presents a summary overview of authorizations for capital raisings and convertible bond issuances of all German DAX® and MDAX® companies based on their 2019 annual general meetings.* Responding to inquiries from clients and friends, this booklet now also covers authorizations for share repurchases of all German DAX® and MDAX® companies, also based on their 2019 annual general meetings. The amount of any authorized capital reflected in this booklet takes into account any issuance of shares out of authorized capital entered into the commercial register prior to August 1, 2019. The amount of any convertible bond authorization and underlying conditional capital reflected in this booklet takes into account the issuance of any convertible bonds based on such authorization prior to August 1, 2019 and the amount of conditional capital underlying such convertible bonds. The number of any shares repurchased under a buy-back program reflected in this booklet takes into account the publicly announced share repurchases of the respective issuer until August 1, 2019. Consistent with the nature of the booklet as a summary overview, the information on the authorizations for capital raisings, convertible bond issuances and share repurchases provided herein is limited to the key parameters of the relevant authorized capital, convertible bond authorization, conditional capital and share repurchase authorization. A more detailed analysis of, e.g., the feasibility of a certain capital raising or share repurchase will always require a comprehensive review of the complete wording of the authorization(s) concerned.
    [Show full text]
  • Corporate Governance Presentation Forward-Looking Statements
    April 2021 Corporate Governance Presentation Forward-Looking Statements This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding tafasitamab’s ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab, including ongoing confirmatory trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab as well as the commercial performance of Monjuvi. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,” “could,” “potential,” “possible,” “hope” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent
    [Show full text]
  • FTSE Publications
    2 FTSE Russell Publications FTSE Developed Eurozone Minimum 19 August 2021 Variance Indicative Index Weight Data as at Closing on 30 June 2021 Index weight Index weight Index weight Constituent Country Constituent Country Constituent Country (%) (%) (%) 1&1 AG 0.14 GERMANY Erste Group Bank 0.11 AUSTRIA Muenchener Rueckversicherungs Reg 0.03 GERMANY A2A 0.22 ITALY EssilorLuxottica 0.47 FRANCE Naturgy Energy Group SA 0.38 SPAIN Acciona S.A. 0.1 SPAIN Eurazeo 0.13 FRANCE Neoen S.A. 0.37 FRANCE Ackermans & Van Haaren 0.76 BELGIUM Eurofins Scienti 0.77 FRANCE Neste Oyj 0.36 FINLAND Adidas 0.14 GERMANY Euronext 0.83 FRANCE NN Group 0.07 NETHERLANDS Adyen 0.72 NETHERLANDS Evonik Industries AG 0.1 GERMANY Nokia 0.32 FINLAND Aena SME SA 0.05 SPAIN Evotec 0.35 GERMANY Nokian Tyres 0.26 FINLAND Ageas 0.1 BELGIUM Ferrari NV 0.46 ITALY Nordea Bank Abp 0.2 FINLAND Ahold Delhaize 1.31 NETHERLANDS Ferrovial 0.26 SPAIN Orange 0.67 FRANCE AIB Group 0.03 IRELAND Fielmann 0.68 GERMANY Orion B 1.15 FINLAND Air Liquide 0.54 FRANCE Finecobank 0.24 ITALY ORPEA 0.47 FRANCE Akzo Nobel 0.71 NETHERLANDS Fortum 0.24 FINLAND Pernod Ricard 0.92 FRANCE Ald SA 0.15 FRANCE Fresenius Medical Care 1.04 GERMANY Pirelli & C 0.19 ITALY Allianz SE 0.03 GERMANY Fresenius SE & Co KGaA 0.39 GERMANY Plastic Omnium 0.18 FRANCE Alstom 0.56 FRANCE Fuchs Petrolub Pref SE 0.36 GERMANY ProSiebenSat.1 Media SE 0.19 GERMANY Amplifon 0.26 ITALY Fuchs Petrolub SE 0.32 GERMANY Prosus 0.33 NETHERLANDS Amundi 0.12 FRANCE Galapagos Genomics NV 0.1 NETHERLANDS Proximus 0.76 BELGIUM Andritz 0.6 AUSTRIA Galp Energia SGPS SA 0.19 PORTUGAL Prysmian 0.22 ITALY Argenx S.E 0.25 BELGIUM GEA Group AG 0.17 GERMANY Publicis Groupe 0.36 FRANCE Arkema 0.06 FRANCE Gecina 0.4 FRANCE Puma 0.06 GERMANY Aroundtown SA 0.36 GERMANY Generali 0.41 ITALY Qiagen Nv 1.2 GERMANY ASML Holding 0.25 NETHERLANDS Getlink 0.06 FRANCE Raiffeisen Bank International 0.18 AUSTRIA ASR Nederland 0.04 NETHERLANDS Glanbia 1.08 IRELAND Randstad NV 0.13 NETHERLANDS Atos SE 0.17 FRANCE Grandvision B.V.
    [Show full text]
  • Introductory Report, and We Will Only Report Top-Level Data
    Bertrand Delsuc, Ph.D. biotechradar.eu / Biotellytics September 15th, 2019 THE EUROPEAN LANDSCAPE OF LISTED BIOTECH COMPANIES 2018 REVIEW September 2019 Author: Bertrand Delsuc The European landscape of listed biotech companies: 2018 review This review is an introduction to the universe covered by Biotellytics, publisher of biotechradar.eu, a business intelligence service on the landscape of the European biotech companies listed on the main European stock exchanges. This service aims at providing insights and data at company level for investors, as well as consolidated data for the European level for life sciences professionals. This review will form a basis for more content to be released in the future. This document is intended for a broad audience but more particularly people who are already specialized in the life sciences, without being familiar with the European biotech landscape, and notably the listed side. After a definition of our universe, and a presentation of our selection, we will provide a global overview of the landscape for 2018, based on the following items: IPOs, M&As, R&D pipeline, commercial products, market data, employment, financing and other financial metrics, and deals. All these data will be broken down by country or by (country) cluster, when relevant, in order to have a minimum number of companies for each presented data. Belgium (BE) and the Netherlands (NL) will be taken together, as well as UK and Ireland (IE). Norway (NO) and Finland (FI) will also be gathered into a cluster. The same way, Italia (IT) and Spain (ES) will form the “Southern Europe” cluster. We will end by a snapshot of the characteristics of a “typical” European public biotech company, at the end of 2018.
    [Show full text]
  • Drug Evolution Riding High
    COMPANY PORTRAIT_Evotec Drug evolution riding high Evotec’s history illustrates that biotechnology made in Germany can set standards worldwide. The Max Planck Society is one of the company’s founders and continues to shape it to this day. TEXT DIRK BÖTTCHER n the early 1990s, few people had Evotec is one of Germany’s most suc- until that time, scientists had focused heard of evolutionary molecular cessful biotechnology stories. The com- their research on individual molecules, biology, this field was a source of pany is growing at a breathtaking pace, using their knowledge of biochemistry inspiration for entrepreneurs and utilizing unique technologies, and its to try to achieve specific binding prop- investors. Co-founded by the No- approach based on highly-automated, erties – and, by extension, a desired ef- bel IPrize Laureate Manfred Eigen from industrial-scale translational research fect. Just what might they achieve, the Max Planck Institute for Biophysi- has revolutionized the industry. Most however, if they could investigate a cal Chemistry in Goettingen in 1993, notably, the company has been shaped vast number of these molecules using Hamburg-based Evotec Biosystems set by some of the most remarkable scien- a quasi-evolutionary process in a single out to investigate pharmaceutical sub- tists of our time. device? Eigen’s vision, previously un- stances using the technique Eigen had imaginable, would come to fruition. developed. In a nutshell, the technique FOURTEEN SITES, SIX COUNTRIES, Visiting Evotec in Hamburg today is based on utilizing evolutionary pro- 3,000 EMPLOYEES shows how brilliant his idea was. Es- cesses such as selection by random tablished as a small company with a variations to research and develop First and foremost, they include Man- starting capital of EUR 7 million and a drugs.
    [Show full text]
  • Holdings—Artisan Global Discovery Fund
    Artisan Global Discovery Fund Holdings As of 30 September 2020 Portfolio Holdings Quantity Security Name/Description Price Book Total Market Value Book Pct Assets (%) 61,633 Advanced Micro Devices Inc 81.99 5,053,289.67 2.40 1,115 Adyen NV 1,842.86 2,054,785.76 0.98 11,245 Allegro.eu SA 11.12 125,093.13 0.06 47,964 Aluflexpack AG 26.70 1,280,523.22 0.61 40,677 Ameren Corp 79.08 3,216,737.16 1.53 13,195 Arista Networks Inc 206.93 2,730,441.35 1.30 37,090 Ascendis Pharma A/S 154.32 5,723,728.80 2.72 25,854 Atlassian Corp PLC 181.79 4,699,998.66 2.24 136 Belimo Holding AG 7,552.34 1,027,118.03 0.49 39,307 Blackline Inc 89.63 3,523,086.41 1.68 137,264 Boston Scientific Corp 38.21 5,244,857.44 2.49 99,644 Burberry Group PLC 20.02 1,995,090.27 0.95 15,339 Burlington Stores Inc 206.09 3,161,214.51 1.50 47,843 Centene Corp 58.33 2,790,682.18 1.33 31,532 Ceridian HCM Holding Inc 82.65 2,606,119.80 1.24 5,803 Cintas Corp 332.83 1,931,412.49 0.92 166,141 Clarivate PLC 30.99 5,148,709.59 2.45 40,197 Cognex Corp 65.10 2,616,824.70 1.24 17,749 Cree Inc 63.74 1,131,321.26 0.54 28,674 CTS Eventim AG & Co KGaA 48.37 1,387,055.43 0.66 5,189 DexCom Inc 412.23 2,139,061.47 1.02 243,627 E.ON SE 11.05 2,691,755.32 1.28 4,470 Eurofins Scientific SE 791.64 3,538,616.24 1.68 47,571 Evotec SE 26.46 1,258,689.63 0.60 24,951 First Republic Bank 109.06 2,721,156.06 1.29 56,389 Fortive Corp 76.21 4,297,405.69 2.04 13,860 Genmab A/S 363.11 5,032,736.97 2.39 20,003 Gerresheimer AG 111.90 2,238,285.33 1.06 46,806 Global Payments Inc 177.58 8,311,809.48 3.95 29,434 Guidewire
    [Show full text]
  • [Iito] in a Nutshell
    Visibility for your Business – In a Nutshell Banner Advertising at [LSE] Life-Sciences-Europe.com Ad Offer 0 Visibility for your brand, your business model, and products & services 0 Visibility to global decision makers interested in the European life sciences Visibility for Your Business 0 Visibility 24/7, all year long, to senior managers who stay & return to our portals 0 Several banners at the same time offer you a powerful storytelling approach 0 Putting your content marketing back into the ad: open, transparent & effective [iito] Concept 0 We created one single entry-point to the whole European life sciences 0 The most powerful & time-efficient way to keep track of what’s going on in the Best Content + Readers European business for free; with news, deals, persons, organisations covered = Best Advertising 0 Content selection completely separated from advertising (no “pay-to-play”) 0 High-quality content attracts senior level readers who come, stay & return 0 The only pictures on the portals are openly labelled banner ads, guaranteeing perfect attention without annoying the readers Web Portal 0 [LSE] Life-Sciences-Europe.com (including six regional subportals) 0 The world’s most comprehensive free European life science business info source [LSE] Life-Sciences-Europe 0 100,000 web pages online: news, organisations, deals, persons, products & events 0 210,000 monthly page views and 65,000 monthly visits* 0 Average number of pages viewed per visit: more than 3 0 Average time per visit: more than 4 minutes 0 90% of visitors enter the portals directly (i.e., not via search engines) Search Engines 0 Excellent Google rankings: on 1st page of Google search results..
    [Show full text]